biopharma stock list update: orex, trgt

In red positive intraday performance, we signal:

- we sold OREX (NASDAQ) at 6,45 with 20% gain

- TRGT (NASDAQ) surpassing 8 usd, up 6% to 8,4 usd
- CYTR (NASDAQ) up 8%

- INCY (NASDAQ) up 4,5% to 4 usd

- GTXI (NASDAQ) up 5,5%

- NGSX (NASDAQ) up 5% well above 7 usd

- OCLS (NASDAQ) up 7,5%

- We have added  IDIX (NASDAQ) with strong  consensus and SNTS(nasdaq) with a  FDA decison for its product by december, both for LT

- DDSS (NASDAQ):

Labopharm receives complete response letter from the U.S. FDA for novel antidepressant, no safety or efficay issues, manifacturig issues, we are still  holding the stock in spite of possible today sell off

TICKER                       BUY AREA          QUOTE NOW     POSITION            DRIVER

IDIX (NASDAQ)        USD  4,44              5    LONG TERM      STRONG CONSENSUS      

SNTS (NASDAQ)     USD   2,81              3      LONG TERM    FDA REVIEW Zegerid BY DECEMBER

BFRM (NASDAQ)        USD   2,85           2            LONG TERM OVERSOLD CONDITIONS

OCLS (NASDAQ) USD 2,85     2,75          LONG TERM    MORE UPSIDE

TRGT (NASDAQ) USD 5,5          8,4  STRONG BUY     Targacept's TC-5214 results

OREX (NASDAQ) USD 5,35     6,45 SOLD(+20%)  

FOLD (NASADQ) USD 10           10,4  LONG TERM     PLICERA, AMIGAL STRONG CONSENSUS

SOMX (NASDAQ) USD 1,10       1,38   SOLD (+25%)    

DDSS (NASDAQ)  USD 2,65      2     SHORT TERM   TRAZODONE FDA PDUFA 7/18/09

XNPT (NASDAQ)  USD 21,85      20,5    LONG TERM    XP19986  POSITIVE TRIAL 6/30/09

VNDA (NASDAQ) 12,1                 12,95        REBUYING      FANAT APPROVED 5/6/09

CYTR (NASDAQ)   USD 1,02      1,2        LONG TERM    STRONG CONSENSUS

JAZZ (NASDAQ)    USD 4,95     4       LONG TERM         STRONG CONSENSUS

PARD (NASDAQ)    USD 5          5,9     PROFIT TAKING(+18%)     

PARD (NASDAQ) USD 6,6 rebought 7/2    7,1  LONG TERM       STRONG CONSENSUS

INCY (NASDAQ) USD 3,5         4    LONG TERM            STRONG CONSENSUS

ISTA (NASDAQ) USD 4,1         4,45       LONG TERM          BEPREVE FDA PDUFA  9/12/09

JAV (AMEX)      USD 1,3          1,6       LONG TERM         STRONG CONSENSUS

SLXP (NASDAQ) USD 9,9        11,15  LONG TERM  STRONG CONSENSUS FDA PDUFA 9/9/09

MAPP (NASDAQ) USD 11,3       10  REBUYING LONG TERM STRONG CONSENSUS 

ARYX (NASDAQ) USD            4,5       SOLD 2,5 (-45%)

ARRY (NASDAQ) USD 3,1      3,2    LONG TERM           CLINICAL TRIAL 7/8/09

GTXI (NASDAQ)   USD 9,5      8,7     LONG TERM         FDA PDUFA 10/30/09

UTHR (NASDAQ) USD 84         85  LONG TERM        FDA PDUFA 7/30/09

NGSX (NASDAQ) USD 6,4      7,4 LONG TERM        FDA PDUFA 8/16/09

VICL (NASDAQ)  USD 3             2,7    LONG TERM      SWINE FLU

STAA (NASDAQ)  USD 3,3        2,3 LONG TERM   FDA CLEARENCE FOR Epiphany(TM)

ALTH (NASDAQ)  7,9               7,6  LONG TERM          FDA PDUFA 9/24/09

AMAG (NASDAQ) 52,8        50,8  LONG TERM        FDA APPROVES FERAHEME 6/30/09

XOMA (NASDAQ) 1,2    0,78  LONG TERM  OVERSOLD

HEB (AMEX)    3,3(5%OF CAPITAL)  2,25 SOLD(-35%)                                

HEB (AMEX) was rebought after 100% gain (see old posts)

MRNA (NASDAQ)  3,3            1,5      LONG TERM      OVERSOLD

RIGL (NASDAQ) USD 10           14,4     LONG TERM     STRONG CONSENSUS

MITI (NASDAQ) USD 6              5       LONG TERM      OVERSOLD

MNKD (NASDAQ) USD 8,3         7,95    SOLD(-4%)    

SVNT (NASDAQ) USD 7,10        13       SOLD(+90%)

NPSP (NASDAQ) 3,1 USD        4,75     SOLD(+50%)

SCLN (NASDAQ) 2,25 USD        2,7     SOLD (+20%)  LONG TERM ZADAXIN SALES

MAPP (NASDAQ) 8 USD  (posts from 5/26)  PROFIT TAKED(+45%)   LEVADEX

VNDA (NASDAQ) 8 USD (see old post 5/8)  PROFIT TAKED(+80%)     FANAT

CLDA (NASDAQ) 15,7 USD         9,5  LONG TERM   OVERSOLD

CTIC (NASDAQ) 2,10 USD        1,39 SOLD (-35%)

ANPI (NASDAQ) 2 USD           1,39 SOLD(-30%)

MEDX (NASDAQ) 7,5 USD   8,7 PROFIT TAKING(+20%)  LTERM RECENT PRODUCTS RESULTS

MNTA (NASDAQ) 8,9 USD      11,4   LONG TERM   STRONG CONSENSUS

ACAD (NASDAQ) 2,6 USD     2,35       LONG TERM  CLINICAL DATA  3 Q.

ACOR (NASDAQ) 24 USD   23,4   LONG TERM FAMPRIDINE-SR, FDA PDUFA 10/22/09

BDSI (NASDAQ)                           PROFIT TAKED 6,3  (+18%)  

BDSI (NASDAQ)  6,6 rebought   5,7     SHORT TERM    ONSOLIS APPROVED BY FDA

DNDN (NASDAQ)  22 USD (see old post 4/27) 23,3  LONG TERM  PROVENGE

SPPI (NASDAQ)  4 USD (see ols post 5/12)    6/12 PROFIT TAKING (+35%)

SPPI (NASDAQ)  5,85 USD         7,4     PROFIT TAKING(+28%) 

SPPI (NASDAQ)  6,5 USD rebought 7/2   5,9  LT  ZEVALIN FDA PDUFA  09/07/09

FUSILEV PDUFA 08/10/09